The Colonic Transit Time: a Modifiable Determinant of Intestinal Production and Uptake of Microbial Metabolites?

Constipation Clinical Trial

Official title:

The Colonic Transit Time: a Modifiable Determinant of Intestinal Production and Uptake of Microbial Metabolites?

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01869751
• Other study ID #: S55296
• Status: Withdrawn
• Start date: May 2013
• Est. completion date: December 2018

Study information

• Verified date: April 2020
• Source: Universitaire Ziekenhuizen Leuven
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Chronic kidney disease is associated with the accumulation of various metabolites, i.e., uremic retention solutes. Evidence is mounting that the colonic microbiome contributes substantially to these uremic retention solutes. Indoxyl sulfate and p-cresyl sulfate are among the most extensively studied gut microbial metabolites, and are associated with cardiovascular disease, chronic kidney disease progression and overall mortality. Colonic transit time is an important determinant of intestinal generation and uptake of bacterial metabolites. However, it is unknown if accelerating the colonic transit time reduces the intestinal generation and uptake of indoxyl sulfate and p-cresyl sulfate. Prucalopride is a selective, high-affinity 5-HT4 receptor agonist with a stimulating effect on colonic motility and transit. It is currently used in treating chronic slow-transit constipation. An observational study will be initiated in non-chronic kidney disease patients with chronic slow-transit constipation necessitating treatment with prucalopride to observe its effect on serum concentrations and intestinal generation of indoxyl sulfate and p-cresyl sulfate.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2018
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Age = 18 and = 85 years

• Chronic slow-transit constipation as defined be 4 criteria:

1. having two or fewer spontaneous complete bowel movements week for a minimum of 6 months

2. having one or more of the following symptoms for at least one-quarter of the time: lumpy/hard stools, a sensation of incomplete evacuation, or straining during defecation.

3. slow transit time as determined by Rx colon transit study ("pellet")

4. without evidence of secondary constipation or primary defecation disorder

• Need of therapy with prucalopride (i.e., inefficacy of dietary changes and laxatives)

• Follow-up visit possible after 4 weeks of treatment

• Written informed consent

Exclusion Criteria:

• History or new diagnosis of organic intestinal disease (e.g., inflammatory bowel disease, malignancy)

• Secondary constipation (drug-induced, endocrine, metabolic or neurological disorders, surgery, known or suspected organic disorders of the large intestine, or megacolon) or primary defecation disorder

• Use of laxatives two days before start of treatment and during treatment period. If there is no spontaneous bowel movement during 3 consecutive days, rescue treatment with bisacodyl and/or enema is allowed if necessary

• Presence of significant co-morbidity (uncontrolled heart, liver and lung disease)

• Pregnancy

• Chronic kidney disease, i.e., estimated glomerular filtration rate (MDRD) < 60 ml/min/m² or need of dialysis therapy

Related Conditions & MeSH terms

• Constipation

Intervention

Drug:
• Prucalopride
Treatment with prucalopride for slow-transit constipation

Locations

Country	Name	City	State
Belgium	University Hospitals Leuven	Leuven	Vlaams-Brabant

Sponsors (1)

Lead Sponsor	Collaborator
Universitaire Ziekenhuizen Leuven

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change in serum concentration of bacterial metabolites	change in serum concentration of bacterial metabolites before and after (4 weeks) treatment of prucalopride	4 weeks
Secondary	change in 24h urinary excretion rate of bacterial metabolites	change in 24h urinary excretion rate of bacterial metabolites before and after (4 weeks) treatment of prucalopride	4 weeks